Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06EPO
|
|||
| Former ID |
DND000092
|
|||
| Drug Name |
PF-4136309
|
|||
| Synonyms |
PF-4136309; 1341224-83-6; INCB-8761; INCB 8761; INCB8761; 857679-55-1; INCB8761(PF-4136309); PF4136309; PF 4136309; CHEMBL2029422; N-[2-[(3S)-3-[[4-hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexyl]amino]pyrrolidin-1-yl]-2-oxoethyl]-3-(trifluoromethyl)benzamide; N-[2-((3S)-3-{[4-Hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexyl]amino}pyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl)benzamide; INCB8761 PF-4136309; INCB8761/PF-4136309; SCHEMBL1377713; GTPL9032; ZNSVOHSYDRPBGI-CBQRAPNFSA-N; MolPort-039-139-774
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H31F3N6O3
|
|||
| Canonical SMILES |
C1CC(CCC1NC2CCN(C2)C(=O)CNC(=O)C3=CC(=CC=C3)C(F)(F)F)(C4=NC=C(C=C4)C5=NC=CC=N5)O
|
|||
| InChI |
1S/C29H31F3N6O3/c30-29(31,32)21-4-1-3-19(15-21)27(40)36-17-25(39)38-14-9-23(18-38)37-22-7-10-28(41,11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6,12-13,15-16,22-23,37,41H,7-11,14,17-18H2,(H,36,40)/t22?,23-,28?/m0/s1
|
|||
| InChIKey |
ZNSVOHSYDRPBGI-CBQRAPNFSA-N
|
|||
| CAS Number |
CAS 1341224-83-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01226797) Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.